# Quantitative Fluorescence Endoscopy Using Durvalumab-680LT in Esophageal Cancer

> **NCT05450484** · PHASE1 · COMPLETED · sponsor: **University Medical Center Groningen** · enrollment: 21 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Fluorescence endoscopy using durvalumab-680LT

## Key facts

- **NCT ID:** NCT05450484
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-05
- **Primary completion:** 2024-11-25
- **Final completion:** 2024-12-01
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05450484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05450484, "Quantitative Fluorescence Endoscopy Using Durvalumab-680LT in Esophageal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05450484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*